Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives Consensus Rating of “Hold” from Brokerages

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has been assigned an average rating of “Hold” from the seven ratings firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $62.1667.

SUPN has been the topic of several research reports. Zacks Research upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Wall Street Zen lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 23rd. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Friday, March 27th. Finally, Craig Hallum set a $65.00 target price on Supernus Pharmaceuticals in a research note on Wednesday, February 25th.

Supernus Pharmaceuticals Price Performance

Shares of SUPN opened at $44.41 on Wednesday. The firm has a market cap of $2.58 billion, a P/E ratio of -87.08, a price-to-earnings-growth ratio of 0.95 and a beta of 0.55. Supernus Pharmaceuticals has a 1 year low of $30.83 and a 1 year high of $59.68. The company has a 50 day simple moving average of $48.68 and a two-hundred day simple moving average of $49.56.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 7,250 shares of Supernus Pharmaceuticals stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $49.60, for a total value of $359,600.00. Following the transaction, the vice president owned 17,044 shares in the company, valued at $845,382.40. The trade was a 29.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 8.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in SUPN. Rubric Capital Management LP purchased a new position in Supernus Pharmaceuticals in the second quarter valued at about $21,908,000. Assenagon Asset Management S.A. purchased a new position in Supernus Pharmaceuticals in the first quarter valued at about $27,428,000. Woodline Partners LP boosted its holdings in Supernus Pharmaceuticals by 63.5% in the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock worth $60,398,000 after acquiring an additional 490,835 shares in the last quarter. SG Americas Securities LLC boosted its holdings in Supernus Pharmaceuticals by 2,847.0% in the first quarter. SG Americas Securities LLC now owns 377,213 shares of the specialty pharmaceutical company’s stock worth $19,498,000 after acquiring an additional 364,413 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in Supernus Pharmaceuticals by 67.1% in the third quarter. Bank of America Corp DE now owns 842,890 shares of the specialty pharmaceutical company’s stock worth $40,282,000 after acquiring an additional 338,584 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.